Systemic Sclerosis-associated Interstitial Lung Disease
📧 Sign up to get email alerts when something new happens for Systemic Sclerosis-associated Interstitial Lung Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis [Phase 2]
Phase 2 clinical trial evaluating inhaled AP01 for progressive pulmonary fibrosis is currently recruiting, with no results yet reported.
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD
A clinical trial is evaluating double immunosuppression with or without an anti-fibrotic therapy for systemic sclerosis-associated interstit…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan
A post-marketing surveillance study in Japan evaluating long-term use of Ofev (nintedanib) for systemic sclerosis-associated interstitial lu…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease [Phase 2]
Phase 2 study evaluating the efficacy and safety of vixarelimab in idiopathic pulmonary fibrosis and systemic sclerosis-associated interstit…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: Western Sweden Systemic Sclerosis Project
A systemic sclerosis (scleroderma) trial in Western Sweden, sponsored by Sahlgrenska University Hospital, is currently recruiting and evalua…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease [Phase 2, Phase 3]
Clinical trial update on belimumab for systemic sclerosis-associated interstitial lung disease, spanning Phase 2 and Phase 3, currently recr…
-
EMA approval · 2026-01-06EMA Authorised: Ofev (nintedanib) — Boehringer Ingelheim International GmbH
The European Medicines Agency authorised a label expansion for Ofev (nintedanib) to cover additional interstitial lung diseases, including s…
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: Description of the Functional Evolution of Diffuse Infiltrating Pneumonia Associated With Systemic Scleroderma.
A completed clinical trial update describes the functional evolution of diffuse infiltrating pneumonia in patients with systemic sclerosis.
-
CLINICAL_TRIALS research · 2025-12-08Clinical Trial Update: A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis
A long-term observational registry is underway to observe the effects of nintedanib in people with scleroderma-related interstitial lung dis…
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
Clinical trial update indicating ongoing collection of airway, blood, and/or urine specimens from participants for research studies.
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) [Phase 2]
Phase 2 safety and efficacy trial of tulisokibart (MK-7240/PRA023) for diffuse cutaneous systemic sclerosis-associated interstitial lung dis…
-
CLINICAL_TRIALS trial_result · 2025-09-12Clinical Trial Update: Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease [Phase 3]
This clinical trial update notes the completion of a Phase 3 study evaluating cyclophosphamide for systemic sclerosis-associated interstitia…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: Chest CT Biomarkers as Prognostic Predictors in SSc-ILD
Sponsored by Royal Brompton & Harefield NHS Foundation Trust, this clinical trial investigates whether chest CT biomarkers can predict progn…
-
CLINICAL_TRIALS trial_result · 2025-08-19Clinical Trial Update: NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib
A clinical trial update from Taiwan reports long-term outcomes for people with progressive fibrosing interstitial lung diseases who started …
-
CLINICAL_TRIALS research · 2025-05-07Clinical Trial Update: Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD) [Phase 2]
A Phase 2 clinical trial is evaluating the efficacy, safety, and tolerability of Efzofitimod in patients with systemic sclerosis-associated …
-
CLINICAL_TRIALS research · 2025-04-02Clinical Trial Update: MRI for Screening and Monitoring Scleroderma ILD
An update on a clinical trial evaluating MRI for screening and monitoring interstitial lung disease in systemic sclerosis (scleroderma), spo…
-
CLINICAL_TRIALS research · 2025-01-17Clinical Trial Update: A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease [Phase 2]
This is a Phase II randomized, double-blind, placebo-controlled trial to evaluate safety, tolerability, efficacy, and pharmacokinetics of Ge…
-
CLINICAL_TRIALS trial_result · 2025-01-06Clinical Trial Update: Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF [Phase 3]
Phase 3 clinical trial evaluating a selective JAK inhibitor for interstitial lung disease due to systemic disease and skin tightness in syst…
-
CLINICAL_TRIALS research · 2024-11-14Clinical Trial Update: Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD
A completed Northwestern University study investigates unique pathogenic macrophages involved in systemic sclerosis-associated interstitial …
-
CLINICAL_TRIALS research · 2024-08-27Clinical Trial Update: Evaluation of HRCT Patterns in Systemic Sclerosis-associated Interstitial Lung Disease
A clinical trial evaluating HRCT patterns in systemic sclerosis-associated interstitial lung disease is currently recruiting.
-
CLINICAL_TRIALS withdrawal · 2024-08-27Clinical Trial Update: Efficacy and Safety of JAK Inhibitors in Systemic Sclerosis-associated Interstitial Lung Disease
A clinical trial evaluating JAK inhibitors for systemic sclerosis–associated interstitial lung disease has been withdrawn.
-
CLINICAL_TRIALS research · 2024-08-12Clinical Trial Update: Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis [Phase 3]
A Phase 3 clinical trial is evaluating the combination of rituximab and mycophenolate mofetil for systemic sclerosis–associated interstitial…
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis [Phase 3]
A Phase 3 trial evaluating the long-term safety of nintedanib in scleroderma-related lung fibrosis has completed and posted results in 2024.
-
CLINICAL_TRIALS trial_result · 2020-11-09Clinical Trial Update: A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) [Phase 1]
Phase 1 trial studying whether nintedanib affects components of birth-control pills in women with systemic sclerosis-associated interstitial…
-
CLINICAL_TRIALS trial_result · 2019-06-18Clinical Trial Update: Abituzumab in SSc-ILD [Phase 2]
Phase 2 trial of abituzumab in systemic sclerosis-associated interstitial lung disease was terminated; results posted in 2019.